Ablynx Announces Positive Phase I Results for Subcutaneous Administration of it’s Anti-thrombotic Nanobody (ALX-0681)
20-Aug-2009 -
Ablynx announced the positive results from its double-blind, randomized, placebo-controlled, single and multiple dose Phase I study with ALX-0681, a subcutaneous formulation of its novel anti-thrombotic Nanobody® that selectively targets von Willebrand factor (vWF). The positive Phase I data ...
Acute Coronary Syndrome
biomarker
Formation
+2